By Fineline Cube 
China-based Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566) announced that it has received clinical approval from the National Medical Products Administration (NMPA) to test its investigational anti-tumor drug JJH201601 liposome for injection. The drug will be tested in patients with advanced head and neck squamous cell carcinoma (HNSCC) in combination with cetuximab and/or toripalimab.
Innovative Liposomal Drug Platform
JJH201601 liposome, developed by Jibeier using its proprietary liposomal drug platform, features a novel compound structure developed through molecular design and pharmacological screening. The drug is delivered via liposomal formulation, which enhances its therapeutic potential and safety profile.
Clinical Development Progress
The drug has completed Phase I trials and is currently the subject of a Phase IIa study in advanced solid tumors as a monotherapy. This new approval expands the potential indications for JJH201601 liposome and represents a significant step forward in the development of targeted therapies for HNSCC.-Fineline Info & Tech